Biomed Realty Trust 8-K Biomed Realty Trust Reports Fourth Quarter and Full-year 2013 Financial Results

Exhibit 99.2

SUPPLEMENTAL OPERATING AND FINANCIAL DATA

DECEMBER 31, 2013

BioMed Realty Trust, Inc.	Corporate Communications Contact	www.biomedrealty.com
17190 Bernardo Center Drive	Rick Howe	(858) 485-9840 phone
San Diego, CA 92128	Senior Director, Corporate Communications	(858) 485-9843 fax
	richard.howe@biomedrealty.com

TABLE OF CONTENTS

DECEMBER 31, 2013

	Page			Page
Fourth Quarter Highlights		3	Common and Preferred Stock Data		20
Investor Information		4	Market Summary		21
Equity Research Coverage		5	Property Listing - Consolidated Portfolio		22-24
Financial and Operating Highlights		6	Development, Redevelopment and Development Potential
Capitalization Summary		7			25
Portfolio Summary		8	Capital Expenditures		26
Consolidated Balance Sheets		9	Property Listing - Unconsolidated Partnerships		27
Consolidated Statements of Operations		10	Lease Expirations		28
Balance Sheet / Operations Statement Detail		11	Expirations by Market		29
FFO, CFFO and AFFO		12	10 Largest Tenants		30
FFO, CFFO and AFFO per Share		13	Same Property Analysis		31
Reconciliation of EBITDA and Adjusted EBITDA		14	Acquisitions, Mergers and Dispositions		32
Reconciliation of Net Operating Income		15	Leasing Activity		33
Interest Expense		16	Tenant Improvements, Leasing Commissions and Tenant Concessions
Coverage Ratios		17			34
Debt Summary		18	Non-GAAP Financial Measure Definitions		35
Debt Maturities		19	Definitions		36

This Supplemental Operating and Financial Data package contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants’ financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company’s target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company’s investment grade credit ratings with the ratings agencies; failure to manage effectively the company’s growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with tax credits, grants and other subsidies to fund development activities; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company’s domestic operations; risks associated with the company’s investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company’s potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company’s dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

All amounts shown in this report are unaudited.

This Supplemental Operating and Financial Data package is not an offer to sell or solicitation to buy securities of BioMed Realty Trust, Inc. Any offers to sell or solicitations to buy securities of BioMed Realty Trust, Inc. shall be made only by means of a prospectus approved for that purpose.

FOURTH QUARTER HIGHLIGHTS

DECEMBER 31, 2013

• Executed 34 leasing transactions during the quarter representing approximately 441,800 square feet, contributing to an operating portfolio leased percentage on a weighted-average basis of approximately 91.4% at quarter end, and comprised of:

• 27 new leases totaling approximately 352,500 square feet, highlighted by:

• a new pre-lease with The Broad Institute, Inc. for approximately 99,500 square feet at 320 Charles Street in Cambridge, Massachusetts;

• a new lease with Moderna Therapeutics, Inc. for approximately 44,000 square feet at 320 Bent Street in Cambridge, Massachusetts; and

• a new lease with Asterias Biotherapeutics, Inc. for 44,000 square feet at Dumbarton Circle in Fremont, California.

• Seven lease renewals totaling approximately 89,300 square feet.

• Approximately 186,700 square feet of positive net absorption during the fourth quarter.

• Same property net operating income on a cash basis for the fourth quarter increased 6.6% as compared to the same period in 2012.

• Core funds from operations (CFFO) was $0.34 per diluted share. Funds from operations (FFO) calculated in accordance with standards established by NAREIT was also $0.34 per diluted share. Adjusted funds from operations (AFFO) for the quarter was $0.31 per diluted share.

• Generated total revenues for the fourth quarter of approximately $158.0 million, up from approximately $138.8 million in the fourth quarter of 2012. Rental revenues for the quarter increased to approximately $118.0 million from approximately $104.0 million in the same period in 2012 and were the highest in the company’s and the industry’s history.

• Acquired additional development potential of 300,000 square feet and 274,000 of pre-development, which includes the Chesterfield property in Durham, North Carolina.

• Reported net income available to common stockholders for the quarter of approximately $10.3 million, or $0.05 per diluted share.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 16.3 million rentable square feet. Additional information is available atwww.biomedrealty.com.

INVESTOR INFORMATION

DECEMBER 31, 2013

Company Information
Corporate Headquarters	Trading Symbol	Transfer Agent	Stock Exchange Listing
17190 Bernardo Center Drive	BMR	Computershare Shareowner Services LLC	New York Stock Exchange
San Diego, CA 92128		250 Royall Street
(858) 485-9840		Canton, MA 02021
(858) 485-9843 (fax)		(877) 296-3711
Please visit our corporate website at:	www.biomedrealty.com
Board of Directors	Senior Management
Alan D. Gold	Alan D. Gold	Jonathan P. Klassen	Robert M. Sistek
Chairman	Chairman and	Senior Vice President,	Vice President, Finance
Daniel M. Bradbury	Chief Executive Officer	General Counsel and Secretary	William F. X. Kane
William R. Brody, M.D., Ph.D.	R. Kent Griffin, Jr.	John P. Bonanno	Vice President,
Barbara R. Cambon	President and	Senior Vice President,	Leasing & Development
Edward A. Dennis, Ph.D.	Chief Operating Officer	Leasing & Development	Denis J. Sullivan, Jr.
Richard I. Gilchrist	Gary A. Kreitzer	Kevin M. Simonsen	Vice President,
Gary A. Kreitzer Theodore D. Roth	Executive Vice President,   Director	Vice President,   Real Estate Legal	Acquisitions James W. Cullinan
M. Faye Wilson	Matthew G. McDevitt	Bruce D. Steel	Vice President, Marketing
	Executive Vice President,   Real Estate	Managing Director,   BioMed Ventures	James R. Berens President
	Greg N. Lubushkin	Stephen A. Willey	Wexford Science & Technology
	Chief Financial Officer	Vice President,	Sandy N. Weeks, Esq.
	Karen A. Sztraicher	Chief Accounting Officer	Senior Vice President and
	Executive Vice President,	Janice L. Kameir	General Counsel
	Asset Management	Vice President,   Human Resources	Wexford Science & Technology Daniel C. Cramer
			Senior Vice President, Development
			Wexford Science & Technology
Tentative Schedule for Quarterly Results
First Quarter 2014	April 30, 2014
Second Quarter 2014	July 30, 2014
Third Quarter 2014	October 29, 2014
Fourth Quarter 2014	February 4, 2015

EQUITY RESEARCH COVERAGE

DECEMBER 31, 2013

BMO Capital Markets	Richard C. Anderson Joshua Patinkin	(212) 885-4180 (212) 883-5102	richard.anderson@bmo.com joshua.patinkin@bmo.com
Cantor Fitzgerald	David Toti Evan Smith	(212)915-1219 (212)915-1220	dtoti@cantor.com evan.smith@cantor.com
Cowen and Company	James Sullivan Tom Catherwood	(646)562-1380 (646)562-1382	james.sullivan@cowen.com tom.catherwood@cowen.com
Green Street Advisors	Jeff Theiler	(949)640-8780	jtheiler@greenst.com
Jefferies & Co.	Omotayo Okusanya David Shamis	(212)336-7076 (212)284-1796	tokusanya@jefferies.com dshamis@jefferies.com
KeyBanc Capital Markets	Jordan Sadler Craig Mailman	(917)368-2280 (917)368-2316	jsadler@keybanccm.com cmailman@keybanccm.com
Morgan Stanley	Vikram Malhotra Vance Edelson	(212)761-7064 (212)761-0078	vikram.malhotra@morganstanley.com vance.edelson@morganstanley.com
Raymond James	Paul D. Puryear William A. Crow	(727)567-2253 (727)567-5294	paul.puryear@raymondjames.com bill.crow@raymondjames.com
Robert W. Baird & Co.	David B. Rodgers Mathew R. Spencer	(216)737-7341 (414)298-5053	drodgers@rwbaird.com mspencer@rwbaird.com
Stifel, Nicolaus & Company, Inc.	Daniel Bernstein Seth P. Cohn	(443)224-1351 (443)224-1354	bernsted@stifel.com cohns@stifel.com
UBS Securities	Ross T. Nussbaum Gabriel Hilmoe	(212)713-4760 (212)713-3876	ross.nussbaum@ubs.com gabriel.hilmoe@ubs.com
Wells Fargo Securities	Brendan Maiorana Young Ku	(443)263-6516 (443)263-6564	brendan.maiorana@wachovia.com young.ku@wachovia.com

FINANCIAL AND OPERATING HIGHLIGHTS

DECEMBER 31, 2013

(In thousands, except per share and ratio amounts)

	Three Months Ended
Selected Operating Data	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Rental revenues	$	118,048		$	116,884		$	108,092		$	102,956		$	103,978
Total revenues		157,993			159,232			159,639			160,450			138,771
EBITDA (1)		97,419			95,093			105,389			95,878			85,018
Adjusted EBITDA (1)		97,735			95,659			94,196			88,396			88,784
Net operating income - cash basis (2)		103,382			100,465			98,031			98,784			92,728
General and administrative expense		11,817			11,934			10,396			10,028			10,608
Acquisition-related expenses		19			907			2,120			2,236			22
Capitalized interest		4,207			3,984			3,176			2,840			2,268
Interest expense, net		27,837			27,870			26,119			25,902			26,745
Operating margin (3)		67.9	%		66.8	%		70.2	%		70.1	%		70.9	%
General and administrative expense / Total revenues		7.5	%		7.5	%		6.5	%		6.2	%		7.6	%
Change in same property net operating income - cash basis (4)		6.6	%		5.7	%		2.5	%		3.5	%		6.1	%
Net income available to common stockholders		10,279			4,247			14,803			8,388			4,516
Net income per share - diluted	$	0.05		$	0.02		$	0.08		$	0.05		$	0.03
FFO - diluted (5)		70,997			67,586			80,514			71,333			59,546
FFO per share - diluted (5)	$	0.34		$	0.33		$	0.40		$	0.41		$	0.36
CFFO - diluted (5)		71,016			68,493			82,634			73,569			59,568
CFFO per share - diluted (5)	$	0.34		$	0.33		$	0.41		$	0.42		$	0.36
AFFO - diluted (5)		65,395			60,719			73,951			81,424			55,004
AFFO per share - diluted (5)	$	0.31		$	0.29		$	0.37		$	0.47		$	0.33
Dividend per share - common stock	$	0.250		$	0.235		$	0.235		$	0.235		$	0.235
CFFO payout ratio (6)		73.5	%		71.2	%		57.3	%		56.0	%		65.3	%
AFFO payout ratio (6)		80.6	%		81.0	%		63.5	%		50.0	%		71.2	%

(1) For definitions and discussion of EBITDA and Adjusted EBITDA, see page 35. For a quantitative reconciliation of the differences between EBITDA, Adjusted EBITDA and net income available to common stockholders, see page 14.

(2) For definitions and discussion of net operating income - cash basis, see page 15.

(3) See page 15 for detail.

(4) Compared to the same period in the prior year. See page 31 for detail.

(5) For definitions and discussion of FFO, CFFO and AFFO, see page 35. For a quantitative reconciliation of the differences between FFO, CFFO, AFFO and net income available to common stockholders, see pages 12 and 13.

(6) See page 13 for detail of the CFFO and AFFO payout ratios.

CAPITALIZATION SUMMARY

DECEMBER 31, 2013

(In thousands, except per share and ratio amounts)

Capitalization		12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Total common shares outstanding			192,115			192,107			191,948			169,055			154,328
Total units outstanding (1)			5,416			5,416			5,416			2,919			2,933
Total common shares and units outstanding			197,531			197,523			197,364			171,974			157,261
Common share price at quarter end		$	18.12		$	18.59		$	20.23		$	21.60		$	19.33
Equity value at quarter end		$	3,579,261		$	3,671,947		$	3,992,675		$	3,714,640		$	3,039,847	��
Preferred stock at liquidation value			—			—			—			—			198,000
Consolidated debt			2,664,834			2,560,173			2,524,960			2,255,941			2,170,983
Total capitalization		$	6,244,095		$	6,232,120		$	6,517,635		$	5,970,581		$	5,408,830
Debt / Total assets			44.6	%		43.4	%		43.1	%		45.1	%		44.9	%
Debt / Total gross assets			39.4	%		38.6	%		38.5	%		40.0	%		39.9	%
Debt / Total capitalization			42.7	%		41.1	%		38.7	%		37.8	%		40.1	%
Coverage Ratios (2)
Net Debt / Adjusted EBITDA (3)			6.7			6.6			6.5			6.3			6.0
Interest coverage			3.9			3.8			4.0			3.8			3.7
Fixed charge coverage			3.5			3.5			3.7			3.2			3.0
Total Consolidated Debt
Secured debt / Total gross assets			10.5	%		10.8	%		11.6	%		10.1	%		10.5	%
Floating rate debt / Total debt			33.3	%		30.4	%		27.0	%		27.1	%		24.1	%
Adjusted floating rate debt / Total debt (4)			12.1	%		8.5	%		13.0	%		11.5	%		7.4	%
Unencumbered real estate / Total real estate			76.7	%		73.9	%		74.3	%		77.7	%		77.0	%
Unencumbered CABR / Total CABR (5)			76.9	%		75.8	%		76.5	%		79.1	%		79.3	%
Unsecured line of credit capacity		$	772,000		$	880,000		$	510,000		$	535,000		$	632,000
Bond Covenants (6)	Requirements
Total outstanding debt / Total assets	Must be £ 60%		40.4	%		39.6	%		39.6	%		41.2	%		41.1	%
Secured debt / Total assets	Must be £ 40%		10.7	%		11.1	%		11.9	%		10.4	%		10.8	%
Consolidated income available for debt service / Annual debt service charge	Must be ³ 1.5X		3.6			3.6			3.7			3.2			3.0
Unencumbered assets / Unsecured debt - Notes due 2020	Must be ³ 150%		253	%		265	%		278	%		257	%		260	%
Unencumbered assets / Unsecured debt - Notes due 2016, Notes due 2022	Must be ³ 150%		252	%		263	%		276	%		255	%		257	%

(1) Includes both operating partnership (OP) and long term incentive plan (LTIP) units outstanding.

(2) For discussion of coverage ratios, see page 35. See page 17 for the calculation of interest and fixed charge coverage ratios. See page 14 for calculation of Adjusted EBITDA.

(3) Net Debt is calculated as debt less (cash and cash equivalents and restricted cash).

(4) Includes effect of interest rate swaps on the Company’s unsecured senior term loan facilities. See page 18 for more information.

(5) For current annualized base rent (CABR) by market, see page 21.

(6) For discussion on bond covenants, see page 36.

PORTFOLIO SUMMARY

DECEMBER 31, 2013

	Gross Book Value		Buildings		Rentable Square Feet		Weighted- Average Leased % (1)
	(In thousands)
Stabilized (2)	$	4,116,424		115		9,544,945		99.1	%
Lease up (2)		1,447,689		60		5,554,641		69.6	%
Total operating portfolio	$	5,564,113		175		15,099,586		91.4	%
Development (3)	$	95,479		4		694,305		59.2	%
Redevelopment (3)		31,944		2		146,000		97.6	%
Unconsolidated partnership portfolio (4)		32,069		3		355,080		77.3	%
Pre-Development (3)		106,999		—		1,057,000		—
Development potential (3)		204,945		—		3,866,000		—
Total portfolio	$	6,035,549		184		21,217,971

(1) Calculated based on gross book value for each asset multiplied by the percentage leased.

(2) See pages 22-24 for detail of consolidated portfolio and page 36 for definitions of terms.

(3) See page 25 for detail of the consolidated portfolio and page 36 for definitions of terms.

(4) See page 27 for detail of the unconsolidated partnership portfolio.

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2013

(In thousands)

	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Assets
Investments in real estate, net	$	5,217,902		$	5,172,102		$	5,131,507		$	4,424,867		$	4,319,716
Investments in unconsolidated partnerships		32,137			31,978			32,250			32,118			32,367
Cash and cash equivalents		34,706			29,230			27,666			18,552			19,976
Accounts receivable, net		8,421			10,580			6,274			35,888			4,507
Accrued straight-line rents, net		173,779			169,272			163,287			155,591			152,096
Deferred leasing costs, net		198,067			202,393			213,567			167,648			172,363
Other assets		307,589			278,600			289,232			164,968			133,454
Total assets	$	5,972,601		$	5,894,155		$	5,863,783		$	4,999,632		$	4,834,479
Liabilities and Equity
Liabilities:
Mortgage notes payable, net	$	709,324		$	716,733		$	821,582		$	569,390		$	571,652
Exchangeable senior notes, net		180,000			180,000			180,000			180,000			180,000
Unsecured senior notes, net		895,083			894,850			894,622			894,397			894,177
Unsecured senior term loans		758,786			755,226			395,676			395,486			405,456
Unsecured line of credit		128,000			20,000			240,000			215,000			118,000
Accounts payable, accrued expenses, and other liabilities		314,383			311,287			281,780			199,731			180,653
Total liabilities		2,985,576			2,878,096			2,813,660			2,454,004			2,349,938
Equity:
Stockholders’ equity:
Preferred stock		—			—			—			—			191,469
Common stock		1,921			1,921			1,919			1,691			1,543
Additional paid-in capital		3,554,558			3,552,595			3,549,082			3,065,589			2,781,849
Accumulated other comprehensive loss, net		(32,923	)		(38,618	)		(43,094	)		(55,480	)		(54,725	)
Dividends in excess of earnings		(583,569	)		(545,819	)		(504,921	)		(474,619	)		(443,280	)
Total stockholders’ equity		2,939,987			2,970,079			3,002,986			2,537,181			2,476,856
Noncontrolling interests		47,038			45,980			47,137			8,447			7,685
Total equity		2,987,025			3,016,059			3,050,123			2,545,628			2,484,541
Total liabilities and equity	$	5,972,601		$	5,894,155		$	5,863,783		$	4,999,632		$	4,834,479

CONSOLIDATED STATEMENTS OF OPERATIONS

DECEMBER 31, 2013

(In thousands, except share and per share data)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Revenues:
Rental	$	118,048		$	116,884		$	108,092		$	102,956		$	103,978
Tenant recoveries		37,597			38,907			32,494			32,637			31,638
Other revenue		2,348			3,441			19,053			24,857			3,155
Total revenues		157,993			159,232			159,639			160,450			138,771
Expenses:
Rental operations		49,891			51,688			41,941			40,553			39,502
Depreciation and amortization		58,781			61,898			63,557			60,764			52,963
General and administrative		11,817			11,934			10,396			10,028			10,608
Acquisition-related expenses		19			907			2,120			2,236			22
Total expenses		120,508			126,427			118,014			113,581			103,095
Income from operations		37,485			32,805			41,625			46,869			35,676
Equity in net loss of unconsolidated partnerships		(208	)		(112	)		(267	)		(319	)		(379	)
Interest expense, net		(27,837	)		(27,870	)		(26,119	)		(25,902	)		(26,745	)
Other income/(expense)		1,136			(687	)		(202	)		(3,190	)		(292	)
Net income		10,576			4,136			15,037			17,458			8,260
Net (income)/loss attributable to noncontrolling interests		(297	)		111			(234	)		(146	)		(93	)
Net income attributable to the Company		10,279			4,247			14,803			17,312			8,167
Preferred stock dividends		—			—			—			(2,393	)		(3,651	)
Cost on redemption of preferred stock		—			—			—			(6,531	)		—
Net income available to common stockholders	$	10,279		$	4,247		$	14,803		$	8,388		$	4,516
Income from continuing operations per share available to common stockholders:
Basic and diluted earnings per share	$	0.05		$	0.02		$	0.08		$	0.05		$	0.03
Net income per share available to common stockholders:
Basic and diluted earnings per share	$	0.05		$	0.02		$	0.08		$	0.05		$	0.03
Weighted-average common shares outstanding:
Basic		190,664,323			190,646,722			186,735,157			159,692,470			152,790,669
Diluted		196,117,552			196,131,643			190,151,166			162,713,677			155,728,210

BALANCE SHEET / OPERATIONS STATEMENT DETAIL

DECEMBER 31, 2013

(In thousands)

	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Restricted cash	$	11,500		$	9,386		$	71,046		$	4,068		$	3,554
Acquired above-market leases, net		15,828			17,052			18,349			12,432			18,099
Acquired below-market ground lease, net		21,983			19,648			19,767			11,310			11,368
Deferred loan costs, net		18,771			20,407			15,442			16,240			17,512
Lease incentives, net		19,639			20,138			20,627			21,140			21,741
Construction loan receivable, net (1)		151,823			120,948			92,567			55,981			21,695
Other		68,045			71,021			51,434			43,797			39,485
Other assets	$	307,589		$	278,600		$	289,232		$	164,968		$	133,454
Security deposits	$	13,728		$	13,538		$	13,667		$	12,186		$	12,417
Dividends and distributions payable		49,383			46,418			46,381			40,413			40,607
Accounts payable, accrued expenses and other liabilities		210,986			207,967			178,125			133,420			114,123
Derivative instruments		2,165			2,620			1,439			5,435			5,285
Acquired below-market leases, net		38,121			40,744			42,168			8,277			8,221
Accounts payable, accrued expenses and other liabilities	$	314,383		$	311,287		$	281,780		$	199,731		$	180,653
	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Lease termination revenue	$	—		$	1,504		$	17,316		$	24,001		$	2,483
Construction loan revenue		2,190			1,824			1,319			807			387
Other revenue		158			113			418			49			285
Other revenue	$	2,348		$	3,441		$	19,053		$	24,857		$	3,155
Rental operations expenses	$	35,450		$	36,222		$	28,397		$	27,165		$	26,753
Real estate taxes		14,441			15,466			13,544			13,388			12,749
Rental operations	$	49,891		$	51,688		$	41,941		$	40,553		$	39,502
Loss on extinguishment of debt	$	—		$	—		$	—		$	—		$	(99	)
Non-cash adjustment for securities		—			—			—			(2,825	)		—
Gain/(loss) on derivative instruments		296			121			—			—			(1	)
Gain on sale of assets		—			230			—			—			—
Other investment loss		(107	)		(1,135	)		—			—			—
Realized gain on investments in equity securities		787			354			82			—			—
Realized gain/(loss) on foreign currency transactions		56			190			7			(160	)		16
Income tax benefit/(expense)		104			(447	)		(291	)		(205	)		(208	)
Other income/(expense)	$	1,136		$	(687	)	$	(202	)	$	(3,190	)	$	(292	)

(1) Represents funding of draws on a $355 million construction loan secured by first priority mortgages on a 1.1 million square foot laboratory, office and retail development project located in Boston, Massachusetts, of which the Company’s total potential funding obligation is $255 million.

FFO, CFFO AND AFFO (1)

DECEMBER 31, 2013

(In thousands)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Reconciliation of net income available to common stockholders to funds from operations excluding acquisition-related expenses (CFFO):
Net income available to common stockholders	$	10,279		$	4,247		$	14,803		$	8,388		$	4,516
Adjustments:
Gain on sale of assets		—			(230	)		—			—			—
Noncontrolling interests in operating partnership		285			118			263			154			86
Depreciation & amortization - unconsolidated partnerships		382			380			367			369			323
Depreciation & amortization - consolidated entities		58,781			61,898			63,557			60,764			52,963
Depreciation & amortization - allocable to noncontrolling interests of consolidated joint ventures		(418	)		(515	)		(164	)		(30	)		(30	)
Funds from operations (FFO) - basic	$	69,309		$	65,898		$	78,826		$	69,645		$	57,858
Interest expense - exchangeable senior notes due 2030 (2)		1,688			1,688			1,688			1,688			1,688
FFO - diluted	$	70,997		$	67,586		$	80,514		$	71,333		$	59,546
Acquisition-related expenses		19			907			2,120			2,236			22
CFFO - diluted	$	71,016		$	68,493		$	82,634		$	73,569		$	59,568
Reconciliation of CFFO to adjusted funds from operations (AFFO):
Adjustments:
Recurring capital expenditures and second generation tenant improvements (3)		(8,028	)		(9,857	)		(12,599	)		(9,795	)		(5,738	)
Leasing commissions		(1,780	)		(1,703	)		(1,985	)		(1,580	)		(1,476	)
Gain on extinguishment of debt		—			—			—			—			(20	)
(Gain)/loss on derivative instruments		(296	)		(121	)		—			—			1
Non-cash adjustment for securities		—			—			—			2,825			—
Non-cash debt adjustments		3,106			3,426			3,059			3,099			3,141
Amortization of lease incentives		563			561			543			627			576
Depreciation included in general and administrative expense		647			629			565			481			510
Non-cash equity compensation		3,285			3,489			3,067			3,011			2,860
Cost on redemption of preferred stock		—			—			—			6,531			—
Straight line rents		(2,983	)		(4,078	)		(4,269	)		(2,605	)		(6,330	)
Share of unconsolidated partnership adjustments (4)		18			24			31			40			34
Fair-value lease revenue		(153	)		(144	)		2,905			5,221			1,878
AFFO - diluted	$	65,395		$	60,719		$	73,951		$	81,424		$	55,004

(1) For definitions and discussion of FFO, CFFO and AFFO, see page 35.

(2) The calculations of FFO, CFFO and AFFO per share diluted include the assumed issuance of common stock pursuant to the exchange provision of the exchangeable senior notes due 2030, which is dilutive based on the “if converted” method for all periods presented since the original issuance in January 2010. Under the if converted method, if the add back of interest charges relating to the exchangeable senior notes due 2030 divided by the corresponding number of common shares issuable upon exchange is dilutive, the potentially issuable shares are included in the calculations of FFO, CFFO and AFFO per diluted share.

(3) Includes revenue enhancing and non-revenue enhancing recurring capital expenditures. Excludes first generation tenant improvements. For definitions of recurring capital expenditures and first and second generation leases, see page 36.

(4) Share of unconsolidated partnership adjustments includes the Company’s share of amortization of deferred loan costs, lease incentives, straight line rents and fair-value lease revenue.

FFO, CFFO AND AFFO PER SHARE (1)

DECEMBER 31, 2013

(In thousands, except share, per share and ratio amounts)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
FFO - basic	$	69,309		$	65,898		$	78,826		$	69,645		$	57,858
FFO - diluted		70,997			67,586			80,514			71,333			59,546
CFFO - diluted		71,016			68,493			82,634			73,569			59,568
AFFO - diluted		65,395			60,719			73,951			81,424			55,004
FFO per share - basic	$	0.35		$	0.33		$	0.41		$	0.42		$	0.37
FFO per share - diluted (2)		0.34			0.33			0.40			0.41			0.36
CFFO per share - diluted (2)		0.34			0.33			0.41			0.42			0.36
AFFO per share - diluted (2)		0.31			0.29			0.37			0.47			0.33
Dividends and distributions declared per common share	$	0.250		$	0.235		$	0.235		$	0.235		$	0.235
CFFO payout ratio		73.5	%		71.2	%		57.3	%		56.0	%		65.3	%
AFFO payout ratio		80.6	%		81.0	%		63.5	%		50.0	%		71.2	%
Weighted-average common shares and units outstanding diluted (3)		197,563,868			197,546,778			191,457,377			164,111,880			157,265,242
Dilutive effect of exchangeable senior notes due 2030 (2)		10,405,224			10,405,224			10,259,496			10,259,496			10,259,496
Weighted-average common shares and units outstanding diluted - FFO, CFFO and AFFO		207,969,092			207,952,002			201,716,873			174,371,376			167,524,738

(1) For definitions and discussion of FFO, CFFO and AFFO, see page 35.

(2) The calculations of FFO, CFFO and AFFO per share diluted include the assumed issuance of common stock pursuant to the exchange provision of the exchangeable senior notes due 2030, which is dilutive based on the “if converted” method for all periods presented since the original issuance in January 2010. Under the if converted method, if the add back of the exchangeable senior notes due 2030 divided by the corresponding number of common shares issuable upon exchange is dilutive, the potentially issuable shares are included in the interest charges relating to calculations of FFO, CFFO and AFFO per diluted share.

(3) The three months ended December 31, 2012 includes 2,937,541 shares of OP and LTIP units, which are considered anti-dilutive for purposes of calculating diluted earnings per share. The three months ended December 31, 2013, September 30, 2013, June 30, 2013, March 31, 2013 and December 31, 2012 include 1,415,135, 1,415,135, 1,306,211, 1,398,203 and 1,537,032 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.

RECONCILIATION OF EBITDA AND ADJUSTED EBITDA (1)

DECEMBER 31, 2013

(In thousands)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Reconciliation of net income available to common stockholders to earnings before interest, taxes, depreciation and amortization (EBITDA) and Adjusted EBITDA:
Net income available to common stockholders	$	10,279		$	4,247		$	14,803		$	8,388		$	4,516
Interest expense, net		27,837			27,870			26,119			25,902			26,745
Interest expense - unconsolidated partnerships		244			251			252			250			263
Income tax (benefit)/expense		(104	)		447			291			205			208
Depreciation & amortization - consolidated entities		58,781			61,898			63,557			60,764			52,963
Depreciation & amortization - unconsolidated partnerships		382			380			367			369			323
EBITDA		97,419			95,093			105,389			95,878			85,018
Noncontrolling interests		297			(111	)		234			146			93
Preferred dividends		—			—			—			2,393			3,651
Cost on redemption of preferred stock		—			—			—			6,531			—
Non-cash adjustment for securities		—			—			—			2,825			—
Gain on sale of assets		—			(230	)		—			—			—
Acquisition-related expenses		19			907			2,120			2,236			22
Elan Corporation lease termination revenue, net		—			—			(13,547	)		(21,613	)		—
Adjusted EBITDA	$	97,735		$	95,659		$	94,196		$	88,396		$	88,784

(1) For definitions and discussion of EBITDA and Adjusted EBITDA, see page 35.

RECONCILIATION OF NET OPERATING INCOME (1)

DECEMBER 31, 2013

(In thousands, except ratio amounts)

	Three Months Ended
	12/31/13			9/30/13			6/30/13				3/31/13			12/31/12
Net income	$	10,576		$	4,136		$	15,037			$	17,458		$	8,260
Equity in net loss of unconsolidated partnerships		208			112			267				319			379
Interest expense, net		27,837			27,870			26,119				25,902			26,745
Other (income)/expense		(1,136	)		687			202				3,190			292
Income from operations		37,485			32,805			41,625				46,869			35,676
Depreciation and amortization		58,781			61,898			63,557				60,764			52,963
General and administrative		11,817			11,934			10,396				10,028			10,608
Acquisition-related expenses		19			907			2,120				2,236			22
Consolidated net operating income	$	108,102		$	107,544		$	117,698			$	119,897		$	99,269
Revenues:
Rental	$	118,048		$	116,884		$	108,092			$	102,956		$	103,978
Tenant recoveries		37,597			38,907			32,494				32,637			31,638
Other revenue (2)		2,348			3,441			19,053		��		24,857			3,155
Total revenues		157,993			159,232			159,639				160,450			138,771
Expenses:
Rental operations		49,891			51,688			41,941				40,553			39,502
Consolidated net operating income	$	108,102		$	107,544		$	117,698			$	119,897		$	99,269
Consolidated net operating income - cash basis (3)	$	103,382		$	100,465		$	98,031			$	98,784		$	92,728
Operating margin (4)		67.9	%		66.8	%		70.2	%			70.1	%		70.9	%
Operating expense recovery (5)		75.4	%		75.3	%		77.5	%			80.5	%		80.1	%

(1) For a definition and discussion of net operating income, see page 35.

(2) Includes lease termination income, see page 11 for detail.

(3) Consolidated net operating income - cash basis is calculated as (consolidated net operating income - straight line rents - fair value lease revenue - lease incentive revenue - bad debt expense - other revenue).

(4) Operating margin is calculated as ((rental revenues + tenant recovery revenues - rental operations) / (rental revenues + tenant recovery revenues)).

(5) Operating expense recovery is calculated as (tenant recovery revenues / rental operations).

INTEREST EXPENSE

DECEMBER 31, 2013

(In thousands)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Mortgage notes payable	$	11,699		$	11,969		$	10,675		$	10,004		$	10,103
Exchangeable senior notes		1,688			1,688			1,688			1,688			1,688
Unsecured senior notes		10,334			10,334			10,334			10,334			10,334
Unsecured senior term loan		2,009			1,993			1,988			1,940			2,039
Unsecured line of credit		1,767			1,242			294			461			417
Line of credit fees		576			602			664			656			712
Derivative instruments		867			600			593			560			579
Interest expense, net - cash basis	$	28,940		$	28,428		$	26,236		$	25,643		$	25,872
Non-cash interest expense:
Amortization of fair-value of debt acquired		(509	)		(511	)		(310	)		(189	)		(159	)
Amortization of debt discounts		233			228			225			219			222
Amortization of deferred loan costs		1,504			1,825			1,374			1,351			1,354
Amortization of deferred interest costs		1,698			1,705			1,711			1,718			1,724
Amortization of put/call and preferred returns		178			179			59			—			—
Non-cash debt adjustments		3,104			3,426			3,059			3,099			3,141
Capitalized interest		(4,207	)		(3,984	)		(3,176	)		(2,840	)		(2,268	)
Interest expense, net	$	27,837		$	27,870		$	26,119		$	25,902		$	26,745

COVERAGE RATIOS (1)

DECEMBER 31, 2013

(In thousands, except ratio amounts)

	Three Months Ended
	12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Interest coverage ratio
Adjusted EBITDA	$	97,735		$	95,659		$	94,196		$	88,396		$	88,784
Interest expense:
Interest expense, net		27,837			27,870			26,119			25,902			26,745
Interest expense - unconsolidated partnerships		244			251			252			250			263
Amortization of deferred interest costs		(1,698	)		(1,705	)		(1,711	)		(1,718	)		(1,724	)
Amortization of deferred loan costs		(1,504	)		(1,825	)		(1,374	)		(1,351	)		(1,354	)
Amortization of debt discounts		(233	)		(228	)		(225	)		(219	)		(222	)
Amortization of fair-value of debt acquired		509			511			310			189			159
Total interest expense	$	25,155		$	24,874		$	23,371		$	23,053		$	23,867
Interest coverage ratio		3.9			3.8			4.0			3.8			3.7
Fixed charge coverage ratio
Adjusted EBITDA	$	97,735		$	95,659		$	94,196		$	88,396		$	88,784
Fixed charges:
Interest expense, net		27,837			27,870			26,119			25,902			26,745
Interest expense - unconsolidated partnerships		244			251			252			250			263
Amortization of deferred interest costs		(1,698	)		(1,705	)		(1,711	)		(1,718	)		(1,724	)
Amortization of deferred loan costs		(1,504	)		(1,825	)		(1,374	)		(1,351	)		(1,354	)
Amortization of debt discounts		(233	)		(228	)		(225	)		(219	)		(222	)
Amortization of fair-value of debt acquired		509			511			310			189			159
Principal payments		2,705			2,616			2,232			2,072			2,072
Preferred dividends		—			—			—			2,393			3,651
Total fixed charges	$	27,860		$	27,490		$	25,603		$	27,518		$	29,590
Fixed charge coverage ratio		3.5			3.5			3.7			3.2			3.0

(1) For a discussion of coverage ratios, see page 35.

DEBT SUMMARY

DECEMBER 31, 2013

(Dollars in thousands)

	Stated Rate			Effective Rate			Principal Balance		Unamortized Premium / (Discount)			Carrying Value		Maturity Date
Consolidated Debt:
Mortgage Notes Payable:
9900 Belward Campus Drive		5.64	%		3.99	%	$	10,631	$	599		$	11,230		07/17
9901 Belward Campus Drive		5.64	%		3.99	%		13,091		734			13,825		07/17
Center for Life Science | Boston		7.75	%		7.75	%		334,447		—			334,447		06/14
4320 Forest Park Avenue (1)		4.00	%		2.70	%		21,000		256			21,256		06/15
Hershey Center for Applied Research (1)		6.15	%		4.71	%		13,449		1,426			14,875		05/27
500 Kendall Street (Kendall D)		6.38	%		5.45	%		57,927		2,012			59,939		12/18
Shady Grove Road		5.97	%		5.97	%		143,067		—			143,067		09/16
University of Maryland BioPark I (1)		5.93	%		4.69	%		16,752		1,472			18,224		05/25
University of Maryland BioPark II (1)		5.20	%		4.33	%		62,946		3,930			66,876		09/21
University of Maryland BioPark Garage (1)		5.20	%		4.33	%		4,738		296			5,034		09/21
University of Miami Life Science & Technology Park (1)		4.00	%		2.89	%		20,000		551			20,551		02/16
Total / Weighted-Average on Mortgage Notes Payable		6.66	%		6.31	%		698,048		11,276			709,324
Unsecured Fixed Rate Debt:
Unsecured Exchangeable Senior Notes Due 2030		3.75	%		3.75	%		180,000		—			180,000		01/30
Unsecured Senior Notes Due 2016		3.85	%		3.99	%		400,000		(1,213	)		398,787		04/16
Unsecured Senior Notes Due 2020		6.13	%		6.27	%		250,000		(1,790	)		248,210		04/20
Unsecured Senior Notes Due 2022		4.25	%		4.36	%		250,000		(1,914	)		248,086		07/22
Unsecured Variable Rate Debt:
Unsecured Senior Term Loan Due 2017 - U.S. Dollar (2)		1.82	%		2.63	%		243,596		—			243,596		03/17
Unsecured Senior Term Loan Due 2017 - GBP (3)		2.14	%		2.39	%		165,190		—			165,190		03/17
Unsecured Senior Term Loan Due 2018 (4)		1.67	%		1.97	%		350,000		—			350,000		03/18
Unsecured Line of Credit (5)		1.46	%		1.46	%		128,000		—			128,000		03/18
Total / Weighted-Average on Consolidated Debt		4.14	%		4.22	%	$	2,664,834	$	6,359		$	2,671,193
Share of Unconsolidated Partnership Debt:
BioPark Fremont (50%) (fixed) (1)		3.75	%		3.70	%		1,356		6			1,362		05/14
PREI Secured Construction Loan (20%) (variable)		3.17	%		3.17	%		27,795		—			27,795		08/14
Total / Weighted-Average on Share of Unconsolidated Partnership Debt		3.20	%		3.19	%		29,151		6			29,157
Total / Weighted-Average on Consolidated and Share of Unconsolidated Partnership Debt		4.13	%		4.21	%	$	2,693,985	$	6,365		$	2,700,350

(1) Assumed in connection with the Company’s merger with Wexford Science & Technology in May 2013.

(2) The Company entered into interest rate swap agreements that effectively fix the interest rate on $200 million of the unsecured senior term loan facility due 2017 at 2.81% for the remaining term of the loan, subject to adjustments based on the Company’s credit ratings. Including the effect of these swaps, the weighted-average effective interest rate for the $243.6 million outstanding under the unsecured senior term loan facility due 2017 was 2.63% at December 31, 2013.

(3) The Company amended the unsecured senior term loan facility and converted $156.4 million of outstanding borrowings into British pounds sterling equal to £100 million. The principal balance represents the dollar amount based on the exchange rate of $1.65 to £1.00 at the end of the third quarter. The Company entered into interest rate swap agreements that effectively fix the interest rate on £100 million at 2.39% for the remaining term of the loan, subject to adjustments based on the Company’s credit ratings.

(4) The Company entered into interest rate swap agreements effective October 1, 2013 that effectively fix the interest rate on $200 million of the unsecured senior term loan facility due 2018 at 2.20% for three years, subject to adjustments based on the Company’s credit ratings.

(5) Effective rate excludes facility fee of 25 bps on the entire capacity of the unsecured line of credit, or $900.0 million, which equals approximately $562,500 per quarter.

DEBT MATURITIES

DECEMBER 31, 2013

(In thousands)

Weighted-average debt maturity is 4.8 years for consolidated debt (excluding extension options).

	2014		2015		2016		2017		2018		Thereafter		Total
Consolidated debt:
Mortgage Notes Payable:
Mortgage notes payable	$	341,416	$	30,006	$	166,516	$	30,294	$	45,663	$	84,153	$	698,048
Unsecured debt:
Unsecured exchangeable senior notes due 2030 (1)		—		—		—		—		—		180,000		180,000
Unsecured senior notes due 2016		—		—		400,000		—		—		—		400,000
Unsecured senior notes due 2020		—		—		—		—		—		250,000		250,000
Unsecured senior notes due 2022		—		—		—		—		—		250,000		250,000
Unsecured senior term loan due 2017 - U.S. Dollar		—		—		—		243,596		—		—		243,596
Unsecured senior term loan due 2017 - GBP		—		—		—		165,190		—		—		165,190
Unsecured senior term loan due 2018		—		—		—		—		350,000		—		350,000
Unsecured line of credit		—		—		—		—		128,000		—		128,000
Total unsecured debt		—		—		400,000		408,786		478,000		680,000		1,966,786
Total consolidated debt	$	341,416	$	30,006	$	566,516	$	439,080	$	523,663	$	764,153	$	2,664,834
Share of unconsolidated partnership debt:
BioPark Fremont (50%) (fixed)		1,356		—		—		—		—		—		1,356
PREI secured construction loan (20%) (variable)		27,795		—		—		—		—		—		27,795
Share of total unconsolidated partnership debt	$	29,151	$	—	$	—	$	—	$	—	$	—	$	29,151
Total consolidated and share of unconsolidated partnership debt	$	370,567	$	30,006	$	566,516	$	439,080	$	523,663	$	764,153	$	2,693,985

(1) The holders of the unsecured exchangeable senior notes due 2030 (the “2030 Notes”) have the right to require the Company to repurchase the 2030 Notes, in whole or in part, for cash on each of January 15, 2015, January 15, 2020 and January 15, 2025, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the 2030 Notes plus accrued and unpaid interest.

COMMON AND PREFERRED STOCK DATA

DECEMBER 31, 2013

(Shares in thousands)

	Three Months Ended
Summary of Common Shares	12/31/13			09/30/13			06/30/13			03/31/13			12/31/12
Earnings per share
Weighted-average common shares outstanding		190,664			190,647			186,735			159,692			152,791
Weighted-average OP and LTIP units outstanding		5,416			5,416			3,367			2,924			2,937
Dilutive effect of performance units		38			69			49			98			—
Diluted common shares - EPS		196,118			196,132			190,151			162,714			155,728
Funds from operations
Weighted-average common shares outstanding		190,664			190,647			186,735			159,692			152,791
Weighted-average OP and LTIP units outstanding		5,416			5,416			3,367			2,924			2,937
Dilutive effect of performance units		38			69			49			98			—
Dilutive effect of restricted stock		1,446			1,415			1,306			1,398			1,538
Dilutive effect of exchangeable senior notes due 2030		10,405			10,405			10,260			10,259			10,259
Diluted common shares - FFO		207,969			207,952			201,717			174,371			167,525
Closing common shares, OP and LTIP units outstanding		197,531			197,523			197,364			171,974			157,261
Preferred shares outstanding		—			—			—			—			7,920
High price	$	20.56		$	21.62		$	23.13		$	22.30		$	19.68
Low price	$	17.97		$	17.90		$	18.55		$	19.47		$	18.19
Average closing price	$	18.95		$	19.63		$	21.64		$	20.88		$	19.07
Closing price	$	18.12		$	18.59		$	20.23		$	21.60		$	19.33
Dividends per share - annualized	$	1.00		$	0.94		$	0.94		$	0.94		$	0.94
Closing dividend yield - annualized		5.5	%		5.1	%		4.6	%		4.4	%		4.9	%
Dividends per Share	12/31/13			09/30/13			06/30/13			03/31/13			12/31/12
Common Stock - BMR
Amount	$	0.250		$	0.235		$	0.235		$	0.235		$	0.235
Declared		December 12, 2013			September 16, 2013			June 14, 2013			March 15, 2013			December 12, 2012
Record		December 31, 2013			September 30, 2013			June 28, 2013			March 28, 2013			December 31, 2012
Paid		January 15, 2014			October 15, 2013			July 15, 2013			April 15, 2013			January 15, 2013
Preferred Stock - BMR PrA (1)
Amount		—			—			—			—		$	0.46094
Declared		—			—			—			—			December 12, 2012
Record		—			—			—			—			December 31, 2012
Paid		—			—			—			—			January 15, 2013

(1) The Company voluntarily redeemed all shares of its Series A preferred stock on March 15, 2013, at a redemption price of $25.30217 per share (the sum of the $25.00 per share redemption price and a quarterly dividend of $0.46094 prorated through the redemption date).

MARKET SUMMARY

DECEMBER 31, 2013

	Leased Square Feet			Current (1)									Expiration (2)
Market				Annualized Base Rent			Percent of Annualized Base Rent			Annualized Base Rent per Leased Sq Ft			Annualized Base Rent		Percent of Annualized Base Rent			Annualized Base Rent per Leased Sq Ft
				(In thousands)									(In thousands)
Boston		3,175,494		$	175,937			34.0	%	$	55.40		$	190,347		31.4	%	$	59.94
Maryland		1,875,757			71,177			13.8	%		37.95			87,273		14.4	%		46.53
San Diego		1,794,360			60,133			11.6	%		33.51			74,975		12.4	%		41.78
San Francisco		2,441,023			59,248			11.5	%		24.27			72,090		11.9	%		29.53
New York / New Jersey		1,518,705			53,568			10.4	%		35.27			66,641		11.0	%		43.88
Pennsylvania		949,904			24,102			4.7	%		25.37			28,333		4.7	%		29.83
Cambridge, UK		470,015			17,572			3.4	%		37.39			17,572		2.9	%		37.39
North Carolina		771,467			13,369			2.6	%		17.33			17,363		2.9	%		22.51
Seattle		265,142			11,622			2.2	%		43.83			14,556		2.4	%		54.90
University Related - Other		1,058,335			30,492			5.8	%		28.81			37,184		6.0	%		35.13
Total portfolio / weighted-average		14,320,202		$	517,220			100.0	%	$	36.12		$	606,334		100.0	%	$	42.34
	Percent Leased
Market	Total Operating Portfolio			Development (3)			Redevelopment (3)			Unconsolidated Partnership Portfolio (4)
Boston		98.9	%		—			86.5	%		71.5	%
Maryland		92.4	%		—			100.0	%		—
San Diego		89.7	%		—			—			100.0	%
San Francisco		82.2	%		—			—			—
New York / New Jersey		84.6	%		100.0	%		—			—
Pennsylvania		82.0	%		55.2	%		—			—
Cambridge, UK		99.5	%		—			—			—
North Carolina		89.9	%		—			—			—
Seattle		72.4	%		—			—			—
University Related - Other		84.5	%		—			—			—
Total portfolio (5)		88.9	%		69.3	%		96.2	%		77.3	%
Total portfolio weighted-average leased % (6)		91.4	%		59.2	%		97.6	%		77.3	%

(1) Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2) Annualized base rent at expiration is the monthly contractual rent as of date of expiration of the applicable lease (not including any extension option(s)), multiplied by 12 months.

(3) See page 25 for detail of the consolidated portfolio and page 35 for definitions of terms.

(4) See page 27 for detail of the unconsolidated partnership portfolio.

(5) Calculated based on leased square feet divided by total square feet.

(6) Calculated based on gross book value for each asset multiplied by the percentage leased.

PROPERTY LISTING - CONSOLIDATED PORTFOLIO

DECEMBER 31, 2013

			Property			Rentable Square		Percent of Rentable			Leased Square		Percent Leased
	Property	Acquisition Date	Status (1)	Buildings		Feet		Sq Ft			Feet		12/31/13			9/30/13
	Boston
1	Albany Street	May 31, 2005	Stabilized		2		75,003		0.5	%		75,003		100.0	%		100.0	%
2	320 Bent Street	December 14, 2011	Stabilized		1		195,198		1.2	%		195,137		100.0	%		77.4	%
3	301 Binney Street	December 14, 2011	Stabilized		1		417,290		2.6	%		403,381		96.7	%		96.7	%
4	301 Binney Street Garage	December 14, 2011	Stabilized		1		503 Stalls		n/a			503 Stalls		99.8	%		100.0	%
5	210 Broadway	February 9, 2012	Stabilized		1		64,812		0.4	%		64,812		100.0	%		89.0	%
6	Center for Life Science | Boston	November 17, 2006	Stabilized		1		704,159		4.4	%		696,331		98.9	%		98.9	%
7	Charles Street	April 7, 2006	Stabilized		1		47,912		0.3	%		47,912		100.0	%		100.0	%
8	320 Charles Street	June 18, 2013	Stabilized		1		99,513		0.6	%		99,513		100.0	%		100.0	%
9	Coolidge Avenue	April 5, 2005	Stabilized		1		37,684		0.2	%		34,580		91.8	%		91.8	%
10	21 Erie Street	May 31, 2005	Stabilized		1		48,627		0.3	%		48,627		100.0	%		100.0	%
11	40 Erie Street	May 31, 2005	Stabilized		1		100,854		0.6	%		100,854		100.0	%		100.0	%
12	47 Erie Street Parking Structure	May 31, 2005	Stabilized		1		447 Stalls		n/a			447 Stalls		100.0	%		100.0	%
13	Fresh Pond Research Park	April 5, 2005	Stabilized		6		90,702		0.6	%		89,176		98.3	%		98.3	%
14	50 Hampshire Street	February 9, 2012	Stabilized		1		183,052		1.1	%		183,052		100.0	%		100.0	%
15	60 Hampshire Street	February 9, 2012	Redevelopment		1		41,257		0.3	%		35,703		86.5	%		—
16	Kendall Crossing Apartments	December 14, 2011	Stabilized		1		37 Apts.		n/a			34 Apts.		91.2	%		100.0	%
17	450 Kendall Street (Kendall G)	May 31, 2011	Development		1		63,000		0.4	%		—		—			—
18	500 Kendall Street (Kendall D)	May 31, 2005	Stabilized		1		349,325		2.2	%		344,097		98.5	%		98.5	%
19	675 W. Kendall Street (Kendall A)	May 31, 2005	Stabilized		1		302,919		1.9	%		302,919		100.0	%		100.0	%
20	Sidney Street	May 31, 2005	Stabilized		1		191,904		1.2	%		191,904		100.0	%		100.0	%
21	Vassar Street	May 31, 2005	Stabilized		1		60,845		0.4	%		60,845		100.0	%		84.1	%
	Total Boston				27		3,074,056		19.2	%		2,973,846		96.7	%		93.7	%
	Maryland
22	Beckley Street	December 17, 2004	Stabilized		1		77,225		0.5	%		77,225		100.0	%		100.0	%
23	9900 Belward Campus Drive	July 18, 2012	Lease Up		1		49,317		0.3	%		32,199		65.3	%		70.2	%
24	9901 Belward Campus Drive	July 18, 2012	Stabilized		1		57,152		0.4	%		57,110		99.9	%		99.9	%
25	9911 Belward Campus Drive	May 24, 2006	Stabilized		1		289,912		1.8	%		289,912		100.0	%		100.0	%
26	9920 Belward Campus Drive	May 8, 2007	Stabilized		1		51,181		0.3	%		51,181		100.0	%		100.0	%
27	9704 Medical Center Drive	May 3, 2010	Stabilized		1		122,600		0.8	%		122,600		100.0	%		100.0	%
28	9708-9714 Medical Center Drive	May 3, 2010	Lease Up		3		92,124		0.6	%		16,067		17.4	%		17.4	%
29	1701 / 1711 Research Boulevard	May 9, 2011	Redevelopment		1		104,743		0.7	%		104,743		100.0	%		100.0	%
30	Shady Grove Road	May 24, 2006	Stabilized		4		635,058		4.0	%		635,058		100.0	%		100.0	%
31	Tributary Street	December 17, 2004	Stabilized		1		91,592		0.6	%		91,592		100.0	%		100.0	%
32	University of Maryland BioPark I	May 31, 2013	Stabilized		1		75,517		0.5	%		75,517		100.0	%		100.0	%
33	University of Maryland BioPark II	May 31, 2013	Stabilized		1		235,333		1.5	%		220,148		93.5	%		92.9	%
34	University of Maryland BioPark Garage	May 31, 2013	Stabilized		1		638 Stalls		n/a			582 Stalls		96.0	%		73.0	%
35	50 West Watkins Mill Road	May 7, 2010	Lease Up		1		57,410		0.4	%		20,000		34.8	%		34.8	%
36	55 / 65 West Watkins Mill Road	February 23, 2010	Stabilized		2		82,405		0.5	%		82,405		100.0	%		100.0	%
	Total Maryland				21		2,021,569		12.9	%		1,875,757		92.8	%		92.8	%
	San Diego
37	Balboa Avenue	August 13, 2004	Stabilized		1		35,344		0.2	%		35,344		100.0	%		100.0	%
38	Bernardo Center Drive	August 13, 2004	Stabilized		1		61,286		0.4	%		61,286		100.0	%		100.0	%
39	Coast 9	October 15, 2010	Lease Up		8		162,074		1.0	%		133,425		82.3	%		78.3	%
40	4570 Executive Drive	September 17, 2010	Lease Up		1		125,219		0.8	%		106,757		85.3	%		85.3	%
41	Faraday Avenue	September 19, 2005	Stabilized		1		28,704		0.2	%		28,704		100.0	%		100.0	%
42	Gazelle Court	March 30, 2010	Stabilized		1		176,000		1.1	%		176,000		100.0	%		100.0	%
43	3525 John Hopkins Court	December 28, 2010	Stabilized		1		48,306		0.3	%		48,306		100.0	%		100.0	%
44	3545-3575 John Hopkins Court	August 16, 2006	Lease Up		1		72,192		0.5	%		61,173		84.7	%		84.7	%
45	6114-6154 Nancy Ridge Drive	May 2, 2007	Stabilized		3		196,557		1.2	%		196,557		100.0	%		100.0	%
46	6122-6126 Nancy Ridge Drive	April 25, 2012	Stabilized		1		68,000		0.4	%		68,000		100.0	%		100.0	%
47	6828 Nancy Ridge Drive	April 21, 2005	Lease Up		1		42,138		0.3	%		17,707		42.0	%		42.0	%
48	Pacific Center Boulevard	August 24, 2007	Stabilized		2		66,745		0.4	%		66,745		100.0	%		100.0	%
49	Road to the Cure	December 14, 2006	Lease Up		1		67,998		0.4	%		60,957		89.6	%		65.3	%
50	San Diego Science Center	October 21, 2004	Lease Up		1		105,364		0.7	%		85,650		81.3	%		79.0	%
51	10240 Science Center Drive	September 23, 2010	Stabilized		1		49,347		0.3	%		49,347		100.0	%		100.0	%
52	10255 Science Center Drive	September 24, 2004	Stabilized		1		53,740		0.3	%		53,740		100.0	%		100.0	%
53	Sorrento Plaza	December 18, 2010	Stabilized		2		31,184		0.2	%		31,184		100.0	%		100.0	%

PROPERTY LISTING - CONSOLIDATED PORTFOLIO

DECEMBER 31, 2013

			Property			Rentable Square		Percent of Rentable			Leased Square		Percent Leased
	Property	Acquisition Date	Status (1)	Buildings		Feet		Sq Ft			Feet		12/31/13			9/30/13
	San Diego (Continued)
54	Sorrento Valley Boulevard	December 7, 2006	Lease Up		1		54,924		0.3	%		—		—			—
55	11388 Sorrento Valley Road	September 10, 2010	Stabilized		1		35,940		0.2	%		35,940		100.0	%		100.0	%
56	Summers Ridge	June 8, 2012	Stabilized		—		—		n/a			—		100.0	%		100.0	%
57	Torreyana Road	March 22, 2007	Stabilized		1		81,204		0.5	%		81,204		100.0	%		100.0	%
58	9865 Towne Centre Drive	August 12, 2004	Stabilized		2		94,866		0.6	%		94,866		100.0	%		100.0	%
59	9885 Towne Centre Drive	August 12, 2004	Stabilized		2		104,870		0.7	%		104,870		100.0	%		100.0	%
60	Waples Street	March 1, 2005	Lease Up		1		50,055		0.3	%		21,952		43.9	%		43.9	%
61	Wateridge Circle	November 1, 2011	Stabilized		3		106,490		0.7	%		101,783		95.6	%		95.6	%
	Total San Diego				39		1,918,547		12.0	%		1,721,497		89.7	%		88.4	%
	San Francisco
62	Ardentech Court	November 18, 2004	Stabilized		1		55,588		0.3	%		55,588		100.0	%		100.0	%
63	Ardenwood Venture (2)	June 14, 2006	Lease Up		1		72,500		0.5	%		60,339		83.2	%		83.2	%
64	Bayshore Boulevard	August 17, 2004	Stabilized		3		183,344		1.2	%		183,344		100.0	%		100.0	%
65	Bridgeview Technology Park I	September 10, 2004	Lease Up		2		201,567		1.3	%		106,694		52.9	%		62.1	%
66	Bridgeview Technology Park II	March 16, 2005	Lease Up		1		50,400		0.3	%		28,714		57.0	%		57.0	%
67	550 Broadway Street	April 27, 2012	Stabilized		1		71,239		0.4	%		71,239		100.0	%		100.0	%
68	Dumbarton Circle	May 27, 2005	Stabilized		1		44,000		0.3	%		44,000		100.0	%		—
69	Gateway Business Park	October 26, 2010	Lease Up		4		176,503		1.1	%		145,056		82.2	%		86.7	%
70	Industrial Road	August 17, 2004	Stabilized		1		175,144		1.1	%		175,144		100.0	%		100.0	%
71	Kaiser Drive	August 25, 2005	Lease Up		1		87,953		0.6	%		71,215		81.0	%		56.8	%
72	Pacific Industrial Center	July 11, 2006	Lease Up		1		305,026		1.9	%		252,119		82.7	%		82.7	%
73	Pacific Research Center North	July 11, 2006	Lease Up		6		661,245		4.1	%		523,491		79.2	%		77.8	%
74	Pacific Research Center South	July 11, 2006	Lease Up		3		423,246		2.7	%		263,543		62.3	%		62.3	%
75	Science Center at Oyster Point	October 26, 2010	Stabilized		2		204,887		1.3	%		204,887		100.0	%		100.0	%
76	Woodside Technology Park	February 28, 2013	Stabilized		3		255,650		1.6	%		255,650		100.0	%		100.0	%
	Total San Francisco				31		2,968,292		18.7	%		2,441,023		82.2	%		80.6	%
	New York / New Jersey
77	Ardsley Park	June 23, 2011	Stabilized		5		160,500		1.0	%		160,500		100.0	%		100.0	%
78	Graphics Drive	March 17, 2005	Lease Up		1		72,300		0.5	%		46,386		64.2	%		64.2	%
79	Landmark at Eastview	August 12, 2004	Lease Up		5		800,671		4.7	%		654,299		81.7	%		81.1	%
80	Landmark at Eastview II	August 12, 2004	Stabilized		3		360,520		2.3	%		360,520		100.0	%		100.0	%
81	Landmark at Eastview III	August 12, 2004	Development		2		297,000		1.9	%		297,000		100.0	%		100.0	%
82	One Research Way	May 31, 2006	Lease Up		1		49,421		0.3	%		—		—			—
	Total New York / New Jersey				17		1,740,412		10.7	%		1,518,705		87.3	%		87.0	%
	Pennsylvania
83	George Patterson Boulevard	October 28, 2005	Stabilized		1		71,500		0.4	%		71,500		100.0	%		100.0	%
84	Hershey Center for Applied Research	May 31, 2013	Lease Up		1		80,867		0.5	%		70,939		87.7	%		87.8	%
85	King of Prussia	August 11, 2004	Stabilized		5		374,387		2.3	%		374,387		100.0	%		100.0	%
86	3711 Market Street (3)	May 31, 2013	Stabilized		1		154,793		1.0	%		146,296		94.5	%		94.5	%
87	3737 Market Street (4)	May 31, 2013	Development		1		334,305		2.1	%		184,487		55.2	%		55.2	%
88	Phoenixville Pike	April 5, 2005	Lease Up		1		104,400		0.7	%		39,111		37.5	%		37.5	%
89	Spring Mill Drive	July 20, 2006	Lease Up		1		76,561		0.5	%		63,184		82.5	%		82.5	%
90	900 Uniqema Boulevard	January 13, 2006	Lease Up		1		11,293		0.1	%		—		—			—
91	1000 Uniqema Boulevard	September 30, 2005	Lease Up		1		59,821		0.4	%		—		—			—
	Total Pennsylvania				13		1,267,927		8.0	%		949,904		74.9	%		74.9	%
	Cambridge, UK
92	Granta Park	June 12, 2012	Stabilized		11		472,234		3.0	%		470,015		99.5	%		99.5	%
	Total Cambridge, UK				11		472,234		3.0	%		470,015		99.5	%		99.5	%
	North Carolina
93	Paramount Parkway	July 20, 2010	Stabilized		1		61,603		0.4	%		61,603		100.0	%		100.0	%
94	Patriot Drive	December 17, 2010	Lease Up		1		48,394		0.3	%		40,541		83.8	%		83.8	%
95	Piedmont Triad Research - Wake 90	May 31, 2013	Lease Up		1		475,742		3.0	%		396,734		83.4	%		83.4	%
96	Wake Forest Biotech Place	May 31, 2013	Stabilized		1		242,000		1.5	%		242,000		100.0	%		100.0	%
97	Weston Parkway	December 17, 2010	Stabilized		1		30,589		0.2	%		30,589		100.0	%		100.0	%
	Total North Carolina				5		858,328		5.4	%		771,467		89.9	%		89.9	%

PROPERTY LISTING - CONSOLIDATED PORTFOLIO

DECEMBER 31, 2013

			Property			Rentable Square		Percent of Rentable			Leased Square		Percent Leased
	Property	Acquisition Date	Status (1)	Buildings		Feet		Sq Ft			Feet		12/31/13			9/30/13
	Seattle
98	Elliott Avenue	August 24, 2004	Lease Up		1		151,194		0.9	%		84,657		56.0	%		56.0	%
99	530 Fairview Avenue	January 12, 2006	Stabilized		1		96,305		0.6	%		96,305		100.0	%		100.0	%
100	Monte Villa Parkway	August 17, 2004	Lease Up		1		51,000		0.3	%		30,167		59.2	%		59.2	%
101	�� 217th Place	November 21, 2006	Lease Up		1		67,799		0.4	%		54,013		79.7	%		79.7	%
	Total Seattle				4		366,298		2.2	%		265,142		72.4	%		72.4	%
	University Related - Other
102	BRDG Park at Danforth Plant Science Center	May 31, 2013	Lease Up		1		109,731		0.7	%		91,180		83.1	%		80.5	%
103	4320 Forest Park Avenue	May 31, 2013	Stabilized		1		152,664		1.0	%		152,664		100.0	%		100.0	%
104	Heritage @ 4240	May 31, 2013	Lease Up		1		183,842		1.2	%		111,500		60.6	%		60.6	%
105	Innovation Research Park at ODU I	May 31, 2013	Stabilized		1		95,634		0.6	%		86,094		90.0	%		90.0	%
106	Innovation Research Park at ODU II	May 31, 2013	Lease Up		1		95,670		0.6	%		71,661		74.9	%		74.9	%
107	Trade Centre Avenue	August 9, 2006	Stabilized		2		78,023		0.5	%		78,023		100.0	%		100.0	%
108	University of Miami Life Science & Technology Park	May 31, 2013	Lease Up		1		258,680		1.6	%		189,229		73.2	%		71.1	%
109	University Tech Park at IIT	May 31, 2013	Stabilized		1		128,000		0.8	%		128,000		100.0	%		100.0	%
110	Walnut Street	July 7, 2006	Stabilized		4		149,984		0.9	%		149,984		100.0	%		100.0	%
	Total University Related - Other				13		1,252,228		7.9	%		1,058,335		84.5	%		83.9	%
	Total				181		15,939,891		100.0	%		14,045,691		88.1	%		87.0	%

(1) For a definition of Property Status, see page 36.

(2) The Company owns 87.5% of the limited liability company that owns the Ardenwood Venture property.

(3) The Company owns 60% of the limited liability company that owns the 3711 Market Street property.

(4) The Company owns 68% of the limited liability company that owns the 3737 Market Street property.

DEVELOPMENT, REDEVELOPMENT AND DEVELOPMENT POTENTIAL

DECEMBER 31, 2013

(Dollars in thousands)

Property	Market	Rentable Square Feet		Percent Leased			Investment to Date (1)		Estimated Total Investment (2)		Estimated In-Service Date (3)
Development:
450 Kendall Street (Kendall G)	Boston		63,000		—			10,900		44,100		Q3 2015
Landmark at Eastview III	New York / New Jersey		297,000		100.0	%		15,900		152,700		Q3 2015
3737 Market Street	Pennsylvania		334,305		55.2	%		50,600		99,400		Q4 2014
Total / weighted-average			694,305		69.3	%	$	77,400	$	296,200
Redevelopment:
60 Hampshire Street	Boston		41,257		86.5	%	$	4,800	$	14,800		Q4 2014
1701 / 1711 Research Blvd	Maryland		104,743		100.0	%		20,100		34,200		Q1 2014
Total / weighted-average			146,000		96.2	%	$	24,900	$	49,000
Total							$	102,300	$	345,200

Development Potential:			Estimated		Total
	Pre-Development		Developable		Development
Market	Square Feet		Square Feet		Potential
Boston		—		50,000		50,000
Maryland		—		974,000		974,000
San Diego		275,000		—		275,000
San Francisco		400,000		1,594,000		1,994,000
New York / New Jersey		—		667,000		667,000
Pennsylvania		—		103,000		103,000
Cambridge, UK		—		138,000		138,000
North Carolina		274,000		—		274,000
Seattle		108,000		40,000		148,000
University Related - Other		—		300,000		300,000
Total		1,057,000		3,866,000		4,923,000

(1) Includes amounts paid for acquiring the property, landlord improvements and tenant improvement allowances, but for Redevelopment properties excludes any amounts accrued, and payroll, interest or operating expenses capitalized, through December 31, 2013.

(2) Includes construction costs associated with speculative leasing.

(3) Management’s estimate of the time in which construction is substantially completed. A project is considered substantially complete and held available for occupancy upon the completion of tenant improvements, but no later than one year from cessation of major construction activity. Upon completion, management expects the property to enter the Same Property portfolio one year subsequent to the in-service date.

CAPITAL EXPENDITURES

DECEMBER 31, 2013

(Dollars in thousands)

Capital Expenditures:	Three Months Ended
	12/31/13		9/30/13		6/30/13			3/31/13		12/31/12
Development / Pre-Development (1)	$	63,650	$	42,184	$	(7,695	)	$	3,241	$	1,832
Redevelopment		2,219		752		494			1,395		1,411
Tenant improvements - first generation (2)		8,257		5,572		6,446			13,933		11,831
Recurring capital expenditures and second generation tenant improvements (2) (3)		8,028		9,857		12,599			9,795		5,738
Other capital		5,254		8,532		12,144			10,886		7,853
Total capital expenditures	$	87,408	$	66,897	$	23,988		$	39,250	$	28,665

Capitalized Interest:	Investment		Three Months Ended
	to Date (4)		12/31/13			9/30/13			6/30/13			3/31/13			12/31/12
Development	$	77,400	$	695		$	1,367		$	522		$	—		$	—
Redevelopment		24,900		330			294			297			611			630
Other Capital Improvements (5)		174,400		2,165			947			948			755			742
Pre-Development		117,800		1,017			1,376			1,409			1,474			896
Total capitalized interest	$	394,500	$	4,207		$	3,984		$	3,176		$	2,840		$	2,268
Average interest rate capitalized				4.75	%		4.88	%		5.24	%		5.20	%		5.22	%

(1) Projects include funds from tax credit dollars received during the quarter. Negative amounts reflect an excess in tax credit benefits received over expenditures incurred during the quarter.

(2) For definitions of first and second generation leases, see page 36.

(3) Includes revenue enhancing and non-revenue enhancing recurring capital expenditures. For a definition of recurring capital expenditures, see page 36.

(4) Includes amounts paid for acquiring the property, landlord improvements and tenant improvement allowances, but for Development and Redevelopment properties excludes any amounts accrued, and payroll, interest or operating expenses capitalized, through December 31, 2013.

(5) Includes improvements on operating properties, including major tenant improvement projects on properties which are not considered to be in Development, Redevelopment or Pre-development during the three months ended December 31, 2013.

PROPERTY LISTING - UNCONSOLIDATED PARTNERSHIPS

DECEMBER 31, 2013

(Dollars in thousands)

Rentable

Leased

Property

Square

Square

Percent Leased

Property

Acquisition Date

Status (1)

Buildings

Feet

Feet

12/31/13

9/30/13

Market

McKellar Court

McKellar Court

September 30, 2004

Stabilized

1

72,863

72,863

100.0

%

100.0

%

San Diego

PREI

650 E. Kendall Street (Kendall B)

April 4, 2007

Lease Up

1

282,217

201,648

71.5

%

71.5

%

Boston

350 E. Kendall Street Garage (Kendall F)

April 4, 2007

Stabilized

1

1,409 Stalls

1,409 Stalls

100.0

%

100.0

%

Boston

Total assets	$	271,909
Total debt (2)		151,968
Current annualized base rent		12,868
BioMed’s net investment in unconsolidated partnerships	$	32,069
BioMed’s pro rata share of debt		29,151
BioMed ownership percentage		20	%

(1) For a definition of Property Status, see page 36.

(2) McKellar Court’s debt is payable to BioMed Realty, L.P. and is included in investments in unconsolidated partnerships on the Company’s consolidated balance sheet.

LEASE EXPIRATIONS

DECEMBER 31, 2013

The weighted-average remaining lease terms are 7.8 years for the consolidated portfolio and 7.9 years for the total portfolio.

						Current (1)							Expiration (2)
Expiration	Leased Square Feet		Percent of Leased Square Feet			Annualized Base Rent		Percent of Annualized Base Rent			Annualized Base Rent per Leased Square Feet		Annualized Base Rent		Percent of Annualized Base Rent			Annualized Base Rent per Leased Square Feet
						(In thousands)							(In thousands)
Month-to-month		10,080		0.1	%	$	300		0.1	%	$	29.76	$	300		—		$	29.76
First quarter 2014		51,630		0.4	%		900		0.2	%		17.43		900		0.1	%		17.43
Second quarter 2014		474,909		3.3	%		11,517		2.2	%		24.25		11,523		1.9	%		24.26
Third quarter 2014		111,151		0.8	%		7,504		1.5	%		67.51		7,504		1.2	%		67.51
Fourth quarter 2014		177,850		1.2	%		7,532		1.5	%		42.35		7,571		1.2	%		42.57
2014		815,540		5.7	%		27,453		5.4	%		33.66		27,498		4.4	%		33.72
2015		661,717		4.6	%		20,243		3.9	%		30.59		20,738		3.4	%		31.34
2016		1,176,148		8.2	%		45,268		8.8	%		38.49		47,661		7.9	%		40.52
2017		649,002		4.5	%		19,245		3.7	%		29.65		21,130		3.5	%		32.56
2018		1,827,585		12.8	%		81,440		15.7	%		44.56		84,973		14.0	%		46.49
2019		944,668		6.6	%		27,870		5.4	%		29.50		31,081		5.1	%		32.90
2020		879,603		6.1	%		30,436		5.9	%		34.60		35,488		5.9	%		40.35
2021		638,284		4.5	%		19,352		3.7	%		30.32		22,252		3.7	%		34.86
2022		785,347		5.5	%		18,691		3.6	%		23.80		23,939		3.9	%		30.48
2023		1,117,505		7.8	%		55,152		10.7	%		49.35		61,498		10.1	%		55.03
Thereafter		4,814,723		33.6	%		171,770		33.1	%		35.68		229,776		38.1	%		47.72
Total / weighted-average		14,320,202		100.0	%	$	517,220		100.0	%	$	36.12	$	606,334		100.0	%	$	42.34

(1) Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2) Annualized base rent at expiration is the monthly contractual rent as of the date of expiration of the applicable lease (not including any extension option(s)), multiplied by 12 months.

EXPIRATIONS BY MARKET

DECEMBER 31, 2013

	Leased Square Feet
Expiration	Boston		Maryland		San Diego		San Francisco		New York/ New Jersey		Pennsylvania		Cambridge, UK		North Carolina		Seattle		University/ Other		Total
Month-to-month		—		400		6,248		—		630		2,328		—		—		—		474		10,080
2014		79,683		58,497		82,759		136,769		9,243		412,682		1,827		—		11,385		22,695		815,540
2015		54,648		31,048		315,626		116,005		2,833		38,559		22,614		16,492		—		63,892		661,717
2016		416,184		13,098		36,925		273,632		40,613		32,797		1,103		92,192		36,885		232,719		1,176,148
2017		113,908		107,288		104,971		138,627		138,013		25,103		—		—		11,390		9,702		649,002
2018		1,144,843		72,004		338,074		171,584		24,944		14,389		—		15,117		42,628		4,002		1,827,585
2019		31,363		267,033		86,184		161,104		—		41,391		117,919		8,932		49,664		181,078		944,668
2020		359,387		130,846		102,004		71,215		28,899		33,029		136,434		—		—		17,789		879,603
2021		67,968		45,434		8,365		230,311		40,914		71,500		160,290		10,060		—		3,442		638,284
2022		42,385		4,399		17,707		673,346		27,524		6,146		—		—		—		13,840		785,347
2023		563,964		—		219,636		263,543		—		—		26,294		—		—		44,068		1,117,505
Thereafter		301,161		1,145,710		475,861		204,887		1,205,092		271,980		3,534		628,674		113,190		464,634		4,814,723
Total		3,175,494		1,875,757		1,794,360		2,441,023		1,518,705		949,904		470,015		771,467		265,142		1,058,335		14,320,202

10 LARGEST TENANTS

DECEMBER 31, 2013

BioMed’s properties were leased to 309 tenants.

	Tenant	Leased Square Feet		Percent of Leased Sq Ft			Annualized Base Rent Current (1) (In thousands)		Annualized Base Rent per Leased Sq Ft Current		Percent of Annualized Base Rent Current Total Portfolio			Lease Expiration
1	GlaxoSmithKline plc (2)		924,970		6.5	%	$	45,373	$	49.05		8.8	%		June 2026
2	Regeneron Pharmaceuticals, Inc. (3)		1,001,718		7.0	%		40,079		40.01		7.7	%		Multiple
3	Vertex Pharmaceuticals Incorporated (4)		685,286		4.8	%		36,401		53.12		7.0	%		Multiple
4	Beth Israel Deaconess Medical Center, Inc.		362,364		2.5	%		26,823		74.02		5.2	%		July 2023
5	Sanofi (5)		418,003		2.9	%		22,857		54.68		4.4	%		Multiple
6	Ironwood Pharmaceuticals, Inc.		303,259		2.1	%		15,340		50.58		3.0	%		February 2018
7	Children’s Hospital Corporation (6)		200,081		1.4	%		14,459		72.27		2.8	%		May 2023
8	Janssen Biotech, Inc. (Johnson & Johnson)		374,387		2.6	%		9,267		24.75		1.8	%		April 2014
9	Bristol-Myers Squibb (7)		270,047		1.9	%		9,108		33.73		1.8	%		Multiple
10	MedImmune, Inc. (8)		245,808		1.7	%		8,669		35.27		1.7	%		Multiple
	Total / weighted-average (9)		4,785,923		33.4	%	$	228,376	$	47.72		44.2	%

(1) Based on current annualized base rent. Current annualized base rent is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2) The Company’s tenant is Human Genome Sciences (HGS), a wholly owned subsidiary of GlaxoSmithKline plc (GSK).

(3) On April 3, 2013, the Company entered into a build-to-suit transaction to construct two new buildings pre-leased to Regeneron for a 15 year term totaling approximately 297,000 square feet at Landmark at Eastview. 2,833 square feet expire July 2015, 312,525 square feet expire July 2024 and 686,360 square feet expire July 2029.

(4) 81,204 square feet are leased with a subsidiary of Vertex Pharmaceuticals Incorporated. 292,758 square feet expire January 2016, 20,608 square feet expire May 2017, 290,716 square feet expire May 2018 and 81,204 square feet expire January 2019.

(5) 343,000 square feet expire August 2018 and 75,003 square feet expire October 2018.

(6) This tenant guarantees rent on 49,866 square feet leased at the Center for Life Science| Boston.

(7) 77,539 square feet expire February 2015, 29,218 square feet expire April 2018, 133,123 square feet expire December 2022 and 30,167 square feet expire April 2024.

(8) 46,013 square feet expire December 2015, 39,505 square feet expire January 2021 and 160,290 square feet expire December 2021.

(9) Without regard to any early lease terminations and/or renewal options.

SAME PROPERTY ANALYSIS

DECEMBER 31, 2013

(Dollars in thousands)

	Three Months Ended
	12/31/13			12/31/12			Percent Change
Total Same Property Portfolio (1)
Rentable square feet		12,811,030			12,811,030
Percent of total portfolio		78.6	%		98.4	%
Percent leased		88.7	%		88.2	%
Revenues:
Rental	$	104,472		$	102,308			2.1	%
Tenant recoveries		36,296			32,846			10.5	%
Total revenues		140,768			135,154			4.2	%
Expenses:
Rental operations		43,429			40,131			8.2	%
Same property net operating income (2)	$	97,339		$	95,023			2.4	%
Less straight line rents, fair-value lease revenue, lease incentive revenue, and bad debt expense		(768	)		(4,461	)		(82.8	%)
Same property net operating income - cash basis (2) (3)	$	96,571		$	90,562			6.6	%
Rental revenue - cash basis (3)	$	102,692		$	96,660			6.2	%
Same property net operating income, excluding 180 and 200 Oyster Point properties (2) (4)	$	95,240		$	92,075			3.4	%
Same property net operating income - cash basis, excluding 180 and 200 Oyster Point properties (2) (3) (4)	$	94,861		$	87,921			7.9	%

(1) The Same Property portfolio includes properties in the total portfolio that were stabilized or in lease up throughout the full quarter in both the current year and the prior year.

(2) For a definition and discussion of net operating income, see page 35. For a quantitative reconciliation of net operating income to net income in accordance with GAAP, see page 15.

(3) Represents rents on a “cash-on-cash” basis.

(4) The 180 and 200 Oyster Point properties were leased by Life Technologies commencing in the quarter ending June 30, 2013, following a lease termination by Elan Corporation for which the Company received a $46.5 million termination payment.

ACQUISITIONS, MERGERS AND DISPOSITIONS

DECEMBER 31, 2013

Acquisitions and Mergers Detail for 2013:	Market	Closing Date	Rentable Square Feet		Investment		Percent Leased at Acquisition
Property
					(In thousands)
First Quarter 2013
Woodside Technology Park	San Francisco	February 28, 2013		255,650	$	87,000		100.0	%
The Campus at Lincoln Centre (1)	San Francisco	March 20, 2013		—		37,000		n/a
First quarter total				255,650	$	124,000		100.0	%
Second Quarter 2013
Wexford Science & Technology (2)	Various	May 31, 2013		2,555,174	$	669,100		81.2	%
320 Charles Street (3)	Boston	June 18, 2013		99,513		49,518		100.0	%
Second quarter total				2,654,687	$	718,618		81.9	%
Third Quarter 2013
None
Fourth Quarter 2013
None (4)
Total 2013 Acquisitions & Mergers				2,910,337	$	842,618		83.5	%

Dispositions Detail for 2013:	Market	Closing Date	Rentable Square Feet		Gross Proceeds
Property
					(In thousands)
First Quarter 2013
None
Second Quarter 2013
None
Third Quarter 2013
Lucent	University Related - Other	July 31, 2013		21,500	$	5,900
Eisenhower Avenue	Pennsylvania	September 4, 2013		27,750		2,100
Third quarter total				49,250	$	8,000
Fourth Quarter 2013
None
Total 2013 Dispositions				49,250	$	8,000

(1) Includes approximately 280,000 square feet of potential development.

(2) Includes approximately 935,000 square feet in development and approximately 300,000 square feet of potential development. Investment includes the issuance of 5,568,227 shares of common stock of the Company and 336,960 operating partnership units of BioMed Realty, L.P. to the sellers as part of the consideration for the merger.

(3) Investment includes the issuance of 2,034,211 operating partnership units of BioMed Realty, L.P. to the seller as part of the consideration for the acquisition.

(4) Excludes approximately 300,000 and 274,000 square feet of potential development and pre-development acquired during the quarter, respectively.

LEASING ACTIVITY (1)

DECEMBER 31, 2013

	Leased Square Feet			Current Annualized Base Rent per Leased Sq Ft		Pre-Leased Square Feet			Current Annualized Base Rent per Pre-Leased  Sq Ft
Leased Square Feet as of September 30, 2013		14,133,545					13,373
Dispositions		—			—
Expirations		(163,911	)	$	32.66
Terminations		(2,096	)		25.37
Pre-leased delivery		13,373			18.00		(13,373	)	$	18.00
Renewals, amendments, and extensions		89,297			32.42
New leases - 1st generation (2)		63,231			26.70
New leases - 2nd generation (2)		186,763			37.17		102,547			34.38
Leased Square Feet as of December 31, 2013		14,320,202					102,547

	Three Months Ended
Leased Square Feet	12/31/13		9/30/13		6/30/13			3/31/13			12/31/12
Renewals, amendments, and extensions		89,297		110,563		475,250			164,004			368,299
New leases		352,541		229,535		422,770			419,731			256,576
Gross Leasing Activity		441,838		340,098		898,020			583,735			624,875
Net Absorption (3)		186,657		111,265		(45,377	)		(180,165	)		144,516

(1) Leasing activity for leases signed during the periods presented, which may be different than the period of actual occupancy.

(2) For definitions of first and second generation leases, see page 36.

(3) For the quarter ended June 30, 2013, excludes the Regeneron lease for approximately 297,000 square feet at the Landmark at Eastview III property. Under the lease, Regeneron will expand into two new buildings to be constructed by the Company at the property. Regeneron has leased the to-be-built laboratory and office space for a 15-year term.

TENANT IMPROVEMENTS, LEASING COMMISSIONS AND TENANT CONCESSIONS

DECEMBER 31, 2013

	Three Months Ended
	12/31/13		9/30/13		6/30/13		3/31/13		12/31/12
Renewals, Amendments, and Extensions (1)
Number of renewals		7		13		12		13		17
Square feet		89,297		110,563		475,250		164,004		368,299
Tenant improvement costs per square foot (2)	$	5.27	$	—	$	1.42	$	15.21	$	1.23
Leasing commission costs per square foot (2)		3.99		0.65		4.28		0.58		3.54
Tenant concession costs per square foot (2) (3)		0.97		1.21		0.03		2.88		17.01
Total tenant improvement, leasing commission, and tenant concession costs psf	$	10.23	$	1.86	$	5.73	$	18.67	$	21.78
New Leases - 1st Generation (4)
Number of leases		11		16		6		7		5
Square feet		63,231		199,909		383,717		65,779		149,987
Tenant improvement costs per square foot (2)	$	34.00	$	105.63	$	88.59	$	39.46	$	61.97
Leasing commission costs per square foot (2)		6.97		9.81		10.69		7.99		7.25
Tenant concession costs per square foot (2) (3)		0.77		19.96		19.11		4.99		22.00
Total tenant improvement, leasing commission, and tenant concession costs psf	$	41.74	$	135.40	$	118.39	$	52.44	$	91.22
New Leases - 2nd Generation (4)
Number of leases		16		8		2		9		8
Square feet		289,310		29,626		39,053		353,952		106,589
Tenant improvement costs per square foot (2)	$	34.60	$	0.71	$	27.05	$	26.03	$	16.86
Leasing commission costs per square foot (2)		9.33		0.72		8.12		15.90		8.99
Tenant concession costs per square foot (2) (3)		4.20		1.62		—		3.51		10.15
Total tenant improvement, leasing commission, and tenant concession costs psf	$	48.13	$	3.05	$	35.17	$	45.44	$	36.00
Total
Number of renewals/leases		34		37		20		29		30
Square feet		441,838		340,098		898,020		583,735		624,875
Tenant improvement costs per square foot (2)	$	28.59	$	62.15	$	39.78	$	24.50	$	18.47
Leasing commission costs per square foot (2)		7.92		6.04		7.19		10.70		5.36
Tenant concession costs per square foot (2) (3)		3.06		12.26		8.18		3.50		17.04
Total tenant improvement, leasing commission, and tenant concession costs psf	$	39.57	$	80.45	$	55.15	$	38.70	$	40.87

(1) Does not include retained tenants that have relocated to new space or expanded into new space.

(2) Based on management estimates. Assumes all tenant improvement, leasing commission, and tenant concession costs are paid in the calendar year in which the lease is executed, which may be different than the year in which they are actually paid.

(3) Includes both rent concessions due to free or discounted rent periods and lease incentives paid to tenants.

(4) Includes pre-leasing activity and retained tenants that have relocated to new space or expanded into new space within the Company’s portfolio. For definitions of first and second generation leases, see page 36.

NON-GAAP FINANCIAL MEASURE DEFINITIONS

DECEMBER 31, 2013

This document includes certain non-GAAP financial measures that management believes are helpful in understanding our business, as further described below. Our definition and calculation of non-GAAP financial measures may differ from those of other REITs, and therefore, may not be comparable. The non-GAAP measures should not be considered an alternative to net income as an indicator of our performance and should be considered only a supplement to cash flows from operating, investing or financing activities as a measure of liquidity, computed in accordance with GAAP.

FFO, CFFO and AFFO

We present funds from operations, or FFO, FFO excluding acquisition-related expenses, or CFFO, and adjusted funds from operations, or AFFO, available to common shares and OP units because we consider them to be important supplemental measures of our operating performance and believe they are frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO, CFFO and AFFO when reporting their results.

FFO, CFFO and AFFO are intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO, CFFO and AFFO exclude depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, they provide performance measures that, when compared year over year, reflect the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT. As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of depreciable property, impairment charges on depreciable real estate, real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures.

We calculate CFFO by adding acquisition-related expenses to FFO. We calculate AFFO by adding to CFFO: (a) non-cash revenues and expenses, (b) recurring capital expenditures and second generation tenant improvements and (c) leasing commissions.

Our computations may differ from the methodologies for calculating FFO, CFFO and AFFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO, CFFO and AFFO do not represent amounts available for management’s discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO, CFFO and AFFO should not be considered alternatives to net income/(loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as indicators of our liquidity, nor are they indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions. FFO, CFFO and AFFO should be considered only as supplements to net income computed in accordance with GAAP as measures of our operations.

Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA), and Adjusted EBITDA

EBITDA is defined as earnings before interest, taxes, depreciation and amortization. We calculate Adjusted EBITDA by adding to EBITDA: (a) noncontrolling interests in our operating partnership, (b) impairments, (c) dividends payable on and cost on redemption of our series A preferred stock, (d) non-cash adjustments for securities, (e) gains or losses from sales of real estate and (f) acquisition-related expenses, and by subtracting from EBITDA the lease termination fee related to the Elan Corporation lease termination at our Science Center at Oyster Point property in 2013. Management uses EBITDA and Adjusted EBITDA as indicators of our ability to incur and service debt. In addition, we consider EBITDA and Adjusted EBITDA to be appropriate supplemental measures of our performance because they eliminate depreciation and interest, which permits investors to view income from operations without the impact of non-cash depreciation or the cost of debt. However, because EBITDA and Adjusted EBITDA are calculated before recurring cash charges including interest expense and taxes, and are not adjusted for capital expenditures or other recurring cash requirements of our business, their utility is limited.

Coverage Ratios

We present interest and fixed charge ratios as supplemental liquidity measures. Management uses these ratios as indicators of our financial flexibility to service current interest expense and debt amortization from current cash net operating income. In addition, we believe that these coverage ratios represent common metrics used by securities analysts, investors and other interested parties to evaluate our ability to service fixed cash payments. However, because these ratios are derived from Adjusted EBITDA, their utility is limited by the same factors that limit the usefulness of Adjusted EBITDA as a liquidity measure.

Net Operating Income (NOI)

We use net operating income, or NOI, as a performance measure and believe NOI provides useful information to investors regarding our financial condition and results of operations because it reflects only those income and expense items that are incurred at the property level. We compute NOI by adding or subtracting certain items from net income, noncontrolling interest in the operating partnership, gains/losses from investment in unconsolidated partnerships, interest expense, interest income, depreciation and amortization and general and administrative expenses. NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. NOI should not be considered as an alternative to net income as an indication of our performance or to cash flows as a measure of liquidity or ability to make distributions.

DEFINITIONS

DECEMBER 31, 2013

Property Status

Stabilized

Represents operating properties that are more than 90% leased.

Lease up

Represents operating properties that are less than 90% leased.

Redevelopment

Represents properties that we are currently preparing for their intended use, and accordingly are capitalizing interest and other costs as of the end of the quarter.

Pre-development

Represents development properties that are engaged in activities related to planning, entitlement or other preparations for future construction.

Development

Represents properties that we are currently developing through ground up construction.

Development Potential

Represents estimates of the additional rentable square footage that we could put into service if management made the strategic election to pursue additional development.

Lease Type

First Generation

Leases on space which, in management’s evaluation, require significant improvements to prepare or condition the premises for its intended purpose or enhance the value of the property. This generally includes capital expenditures for development, redevelopment or repositioning a property.

Second Generation

Leases which are not considered by management to be first generation leases.

Recurring Capital Expenditures

Recurring capital expenditures exclude (1) items associated with the expansion of a building or its improvements, (2) renovations to a building which change the underlying classification of the building, incurred to prepare or condition the premises for its intended purpose (for example, from office to laboratory) or (3) capital improvements that represent an addition to the property rather than the replacement of property, plant or equipment.

Bond Covenants

Calculated in accordance with the covenants contained in the indenture that governs the terms of the Company’s unsecured senior notes due 2020 and supplemental and base indentures that govern the terms of the Company’s unsecured senior notes due 2016 and unsecured senior notes due 2022, which are included as exhibits to the Company’s Forms 8-K filed with the SEC on April 30, 2010, March 30, 2011, and June 28, 2012, respectively. The covenants for the unsecured senior notes due 2020, unsecured senior notes due 2016, and unsecured senior notes due 2022 are identical, except that the unencumbered total asset value definition for the unsecured senior notes due 2020 includes investments in unconsolidated partnerships accounted for under the equity method of accounting, whereas the unencumbered total asset value definition for the unsecured senior notes due 2016 and unsecured senior notes due 2022 excludes such investments in unconsolidated partnerships.